Nova Eye Medical
Nova Eye Medical is a medical device company focused on developing and commercializing innovative technologies for the treatment of glaucoma. Their proprietary technologies, including the iTrack™ family of canaloplasty devices and the Molteno3® glaucoma drainage device, offer comprehensive treatment options for ophthalmologists. The company collaborates with surgeons and researchers to develop solutions that address unmet needs in glaucoma management.
Short position
Nova Eye Medical (ASX:EYE) has 0.01% of its shares on issue reported as short positions as of 2 Oct 2026, or about 28,623 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.17% in January 2025. EYE is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Nova Eye Medical (EYE) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $34.9MM (source: ASX (Markit))vs $29.3M (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$4.3MM (source: ASX (Markit))vs −$9.1M (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- −$0.015vs −$0.037 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +19.1%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- 71.7%
- Operating margin
- −18.8%
- Net margin
- −12.4%
- FCF margin
- −10.1%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance, ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $34.9MM (source: ASX (Markit)) | $29.3M | $23.3M | $17.0M |
| Gross profit | $25.0MT (source: Derived: trailing 12 months at year end) | $20.1M | $20.2M | $14.4M |
| Operating income | −$6.5MT (source: Derived: trailing 12 months at year end) | −$11.2M | −$9.0M | −$12.0M |
| EBITDA | −$4.4MT (source: Derived: trailing 12 months at year end) | −$9.0M | −$6.0M | −$9.7M |
| EBIT | −$6.5MT (source: Derived: trailing 12 months at year end) | −$11.2M | −$9.0M | −$12.0M |
| Pretax income | −$4.3MT (source: Derived: trailing 12 months at year end) | −$9.1M | −$8.8M | −$17.0M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | −$1.7M |
| NPAT | −$4.3MM (source: ASX (Markit)) | −$9.1M | −$8.8M | −$15.3M |
| Net interest income | −$129.0KT (source: Derived: trailing 12 months at year end) | −$74.0K | $54.0K | $49.0K |
| EPS basic | −$0.015 | −$0.037 | −$0.043 | −$0.096 |
| EPS diluted | −$0.015 | −$0.037 | −$0.043 | −$0.096 |
| Shares | n/a | 284.7M | 228.8M | 195.5M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Full Year Financial ResultsFull Year Results26 Aug 2026via asx_announcements
- Appendix 4E and Annual ReportAnnual Results26 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2026via asx_announcements
- Investor Presentation Half Year ResultsHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- iTrack™ Canaloplasty to be Featured at the 2025 World Glaucoma Congress Media Release iTrack 6 June, 2025Financial Report31 Dec 2025via crawler
- New 18–24 month iTrack data presented at ESCRS 19 Nov, 2025Financial Report31 Dec 2025via crawler
- iTrack™ Canaloplasty to be Featured at the 2025 DOG Annual Congress Media Release General iTrack Molteno3 AlphaRET 25 Sept, 2025Financial Report31 Dec 2025via crawler
Showing 10 of 24 reports